Mazor Robotics announced that the China Food and Drug Administration approved its Renaissance surgical guidance system.
The company's distribution partner in China coordinated seminars and hands-on laboratory experiences for surgeons to learn about the Renaissance system. Mazor has seven Renaissance systems installed throughout Asia.
"China continues to adopt proven and state-of-the-art technologies to offer better patient outcomes, so we believe Renaissance is well-positioned to gain market acceptance. Our distribution partner, Cicel, believes the target market for Renaissance is in the hundreds of hospitals in China. Now, with the CFDA approval, our partner will initiate its marketing and sales process to introduce Renaissance to this important market. Cicel has the local market knowledge and expertise along with the sales, marketing and clinical organization to quickly raise awareness of the Renaissance system," said Ori Hadomi, CEO of Mazor.
More articles on devices:
A 5-year spine-device warranty? Titan Spine is all in
PODs under attack — 5 things to know
39 orthopedic, spine devices receive FDA 510(k) clearance in August